SCHEMBL190291

SCHEMBL190291

OCc1cc(-c2ccc(O)cc2)no1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 4/20 0.72
HSD17B1 P14061 1/20 0.50
HSD17B2 P37059 1/20 0.50
CYP11B1 P15538 1/20 0.47
SMN1; SMN2 Q16637 7/20 0.46
L3MBTL1 Q9Y468 6/20 0.46
RAB9A P51151 5/20 0.46
NPC1 O15118 4/20 0.46
TDP1 Q9NUW8 3/20 0.46
LMNA P02545 1/20 0.46
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
MAPT P10636 2/20 0.43
POLB P06746 1/20 0.43
P2RY14 Q15391 2/20 0.43
CYP2C9 P11712 1/20 0.43
TSPO P30536 1/20 0.43
TMEM97 Q5BJF2 1/20 0.43
SIGMAR1 Q99720 1/20 0.43
JAK2 O60674 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3233333 0.85 NOTUM (0.72) NOTUMSMN1; SMN2L3MBTL1RAB9ANPC1
SCHEMBL8577207 0.84 NOTUM (0.70) NOTUMCYP11B1SMN1; SMN2L3MBTL1RAB9A
SCHEMBL17233329 0.84 NOTUM (0.51) NOTUMHSD17B1HSD17B2CYP11B1SMN1; SMN2
SCHEMBL2901444 0.84 NOTUM (0.70) NOTUMHSD17B1HSD17B2CYP11B1SMN1; SMN2
SCHEMBL3722758 0.84 NOTUM (0.56) NOTUMHSD17B1HSD17B2CYP11B1SMN1; SMN2
SCHEMBL23852324 0.84 NOTUM (0.70) NOTUMCYP11B1SMN1; SMN2L3MBTL1RAB9A
SCHEMBL189884 0.84 NOTUM (0.70) NOTUMSMN1; SMN2L3MBTL1RAB9ANPC1
SCHEMBL4311207 0.84 NOTUM (1.00) NOTUMSMN1; SMN2L3MBTL1RAB9ANPC1
SCHEMBL103310 0.84 NOTUM (0.70) NOTUMSMN1; SMN2L3MBTL1RAB9ANPC1
SCHEMBL1313626 0.83 NOTUM (1.00) NOTUMCYP11B1SMN1; SMN2L3MBTL1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2401263-B1 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK BIOPHARMACEUTICALS CO LTD (KR) 2016-02-17 EP disclosed
US-8828992-B2 Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating Parkinson's disease using the same SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-09-09 US disclosed
EP-2401263-A2 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK Biopharmaceuticals Co., Ltd. (KR) 2012-01-04 EP disclosed
US-20110301150-A1 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK BIOPHARMACEUTICALS CO., LTD. 2011-12-08 US disclosed
WO-2010098600-A2 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK HOLDINGS CO., LTD. (KR) 2010-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301150-A1 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME MAOB, MAOA, PARK7 NOTUM 1260/4885HSD17B1 167/4885HSD17B2 179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.